Drug Trial Radar · NCT02131233
Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)
Last checked: Nov 19, 2026Latest source record: Jan 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
802
Actual
Start
May 23, 2014
Primary completion
Dec 21, 2015
Study completion Dec 19, 2016
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 6, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of reformulated raltegravir (MK-0518) 1200 mg once daily in combination with TRUVADA™ versus raltegravir 400 mg twice daily in combination with TRUVADA™ in HIV-1 infected, treatment-naive participants. The primary hypothesis being tested is that reformulated raltegravir 1200 mg once-daily is non-inferior to raltegravir 400 mg twice-daily, each in combination therapy with TRUVADA™, as assessed by the proportion of participants achieving HIV-1 ribonucleic acid (RNA) \<40 copies/mL at Week 48.
Conditions
- HIV Infection
Interventions
Reformulated RaltegravirDrug
Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily
RaltegravirDrug
Raltegravir 400 mg tablet orally twice daily
TRUVADA™Drug
Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)
Placebo to Reformulated RaltegravirDrug
Placebo to reformulated raltegravir 2 tablets orally once daily
Placebo to RaltegravirDrug
Placebo to raltegravir 1 tablet orally twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving <40 Copies/mL Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Week 48Time frame: Week 48
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.